Guideline on the requirements of external quality assessment programs in molecular pathology

Molecular pathology is an integral part of daily diagnostic pathology and used for classification of tumors, for prediction of prognosis and response to therapy, and to support treatment decisions. For these reasons, analyses in molecular pathology must be highly reliable and hence external quality...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Virchows Archiv : an international journal of pathology 2013-01, Vol.462 (1), p.27-37
Hauptverfasser: van Krieken, J. Han, Normanno, Nicola, Blackhall, Fiona, Boone, Elke, Botti, Gerardo, Carneiro, Fatima, Celik, Ilhan, Ciardiello, Fortunato, Cree, Ian A., Deans, Zandra C., Edsjö, Anders, Groenen, Patricia J. T. A., Kamarainen, Outi, Kreipe, Hans H., Ligtenberg, Marjolijn J. L., Marchetti, Antonio, Murray, Samuel, Opdam, Frank J. M., Patterson, Scott D., Patton, Simon, Pinto, Carmine, Rouleau, Etienne, Schuuring, Ed, Sterck, Silke, Taron, Miquel, Tejpar, Sabine, Timens, Wim, Thunnissen, Erik, van de Ven, Peter M., Siebers, Albert G., Dequeker, Elisabeth
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Molecular pathology is an integral part of daily diagnostic pathology and used for classification of tumors, for prediction of prognosis and response to therapy, and to support treatment decisions. For these reasons, analyses in molecular pathology must be highly reliable and hence external quality assessment (EQA) programs are called for. Several EQA programs exist to which laboratories can subscribe, but they vary in scope, number of subscribers, and execution. The guideline presented in this paper has been developed with the purpose to harmonize EQA in molecular pathology. It presents recommendations on how an EQA program should be organized, provides criteria for a reference laboratory, proposes requirements for EQA test samples, and defines the number of samples needed for an EQA program. Furthermore, a system for scoring of the results is proposed as well as measures to be taken for poorly performing laboratories. Proposals are made regarding the content requirements of an EQA report and how its results should be communicated. Finally, the need for an EQA database and a participant manual are elaborated. It is the intention of this guideline to improve EQA for molecular pathology in order to provide more reliable molecular analyses as well as optimal information regarding patient selection for treatment.
ISSN:0945-6317
1432-2307
1432-2307
DOI:10.1007/s00428-012-1354-4